[HTML][HTML] Beyond weight loss: added benefits could guide the choice of anti-obesity medications
V Guglielmi, S Bettini, P Sbraccia, L Busetto… - Current obesity …, 2023 - Springer
Abstract Purpose of Review To highlight the added benefits of approved and upcoming,
centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and …
centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and …
[HTML][HTML] Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of …
M Olszanecka-Glinianowicz, A Mazur, J Chudek… - Nutrients, 2023 - mdpi.com
Obesity in adults and its complications are among the most important problems of public
health. The search was conducted by using PubMed/MEDLINE, Cochrane Library, Science …
health. The search was conducted by using PubMed/MEDLINE, Cochrane Library, Science …
Five-year weight loss maintenance with obesity pharmacotherapy
MA Weintraub, D D'Angelo, BG Tchang… - The Journal of …, 2023 - academic.oup.com
Context Long-term treatment of obesity with lifestyle changes alone is unsustainable for
most individuals because of several factors including adherence and metabolic adaptation …
most individuals because of several factors including adherence and metabolic adaptation …
A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy
CM Bellanca, E Augello, G Di Benedetto… - Frontiers in …, 2024 - frontiersin.org
Currently 1.3 billion individuals globally engage in smoking, leading to significant morbidity
and mortality, particularly among diabetic patients. There is urgent need for a better …
and mortality, particularly among diabetic patients. There is urgent need for a better …
Use of Contrave, naltrexone with bupropion, bupropion, or naltrexone and major adverse cardiovascular events: a systematic literature review
S Dahlberg, ET Chang, SR Weiss… - … and Obesity: Targets …, 2022 - Taylor & Francis
Naltrexone/Bupropion extended release (ER; Contrave) is an extended-release, fixed-dose
combination medication of naltrexone (8 mg) and bupropion (90 mg) for patients with obesity …
combination medication of naltrexone (8 mg) and bupropion (90 mg) for patients with obesity …
Compositions and methods for reducing major adverse cardiovascular events
P Klassen, K Taylor - US Patent 11,998,542, 2024 - Google Patents
US11998542B2 - Compositions and methods for reducing major adverse cardiovascular events
- Google Patents US11998542B2 - Compositions and methods for reducing major adverse …
- Google Patents US11998542B2 - Compositions and methods for reducing major adverse …